Detalles de la búsqueda
1.
Immunogenicity and safety of HavisureTM vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.
Vaccine
; 41(42): 6215-6220, 2023 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37661535
Resultados
1 -
1
de 1
1
Próxima >
>>